Adam J Schoenfeld - JoVE Visualize

Showing results (21-30 of 68) with videos related to

Pageof 7

Sort By:

Cancer Discovery|April 2, 2024

Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-Small Cell Lung Cancer Resistant to Immune Checkpoint InhibitorsAdam J Schoenfeld, Sylvia M Lee, Bernard Doger de Spéville, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 26, 2025

Gene Copy Deletion of STK11, KEAP1, and SMARCA4: Clinicopathologic Features and Association With the Outcomes of Immunotherapy With or Without Chemotherapy in Nonsquamous NSCLCMalini M Gandhi, Arielle Elkrief, Catherine Gutierrez Moore, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 5, 2019

Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung CancersMorana Vojnic, Daisuke Kubota, Christopher Kurzatkowski, et al.

Cold Spring Harbor Molecular Case Studies|April 3, 2019

Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancersAlexander Drilon, Adam J Schoenfeld, Kathryn C Arbour, et al.

Transplantation and Cellular Therapy|February 24, 2025

Infections in Patients with Solid Tumors Undergoing Adoptive Cellular TherapyViswatej Avutu, Jumanah N Algazaq, Kenneth Seier, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2020

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung CancerAdam J Schoenfeld, Joseph M Chan, Daisuke Kubota, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2023

Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and Recurrent Somatic MLH1 InactivationSoo-Ryum Yang, Erika Gedvilaite, Ryan Ptashkin, et al.

Nature Communications|July 15, 2023

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLCJoao V Alessi, Biagio Ricciuti, Xinan Wang, et al.

JCO Precision Oncology|May 14, 2026

Multimodal Impact of Number of Metastases and Genetic Alterations on Survival in Metastatic Non-Small Cell Lung CancerN Ari Wijetunga, Nikhil P Mankuzhy, Emily S Lebow, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 9, 2022

Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung CancersNoura J Choudhury, Antonio Marra, Jane S Y Sui, et al.

Pageof 7

Showing results (21-30 of 68) with videos related to

Sort By:

Pageof 7

Cancer Discovery|April 2, 2024

Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-Small Cell Lung Cancer Resistant to Immune Checkpoint InhibitorsAdam J Schoenfeld, Sylvia M Lee, Bernard Doger de Spéville, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 26, 2025

Gene Copy Deletion of STK11, KEAP1, and SMARCA4: Clinicopathologic Features and Association With the Outcomes of Immunotherapy With or Without Chemotherapy in Nonsquamous NSCLCMalini M Gandhi, Arielle Elkrief, Catherine Gutierrez Moore, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 5, 2019

Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung CancersMorana Vojnic, Daisuke Kubota, Christopher Kurzatkowski, et al.

Cold Spring Harbor Molecular Case Studies|April 3, 2019

Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancersAlexander Drilon, Adam J Schoenfeld, Kathryn C Arbour, et al.

Transplantation and Cellular Therapy|February 24, 2025

Infections in Patients with Solid Tumors Undergoing Adoptive Cellular TherapyViswatej Avutu, Jumanah N Algazaq, Kenneth Seier, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2020

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung CancerAdam J Schoenfeld, Joseph M Chan, Daisuke Kubota, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2023

Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and Recurrent Somatic MLH1 InactivationSoo-Ryum Yang, Erika Gedvilaite, Ryan Ptashkin, et al.

Nature Communications|July 15, 2023

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLCJoao V Alessi, Biagio Ricciuti, Xinan Wang, et al.

JCO Precision Oncology|May 14, 2026

Multimodal Impact of Number of Metastases and Genetic Alterations on Survival in Metastatic Non-Small Cell Lung CancerN Ari Wijetunga, Nikhil P Mankuzhy, Emily S Lebow, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 9, 2022

Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung CancersNoura J Choudhury, Antonio Marra, Jane S Y Sui, et al.

Pageof 7